Faricimab

Phase 3

Roche Holding AG (RHHBY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Wet Macular Degeneration

View Full Landscape

Drug Information

Target Indication

Wet Macular Degeneration

Clinical Trial

NCT03823300

Last updated: 1/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/15/2022

Vabysmo

Vabysmo is indicated for the treatment of adult patients with: neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DME), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3

Breast Cancer